The minimum BMI for semaglutide (Wegovy) under FDA labeling is 30 without any additional conditions, or 27 with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia
CrossRef Oral prolonged-release dienogest 2 mg and ethinylestradiol 0.02 mg in a 24/4-day regimen for polycystic ovary syndrome-associated hirsutism: a double-blind, randomised, placebo-controlled trial Roger Lobo, Alicyoy Angulo, Alejandro Muoz, Enrico Colli, Hctor F
Prescriptions are required, and these are available for local pickup in Canada only
These structures provide a starting point to design more elaborate and potent drug leads that target SARS-CoV-2 M pro
Boland ML, Oro D, Tolbol KS, et al
The science of semaglutide degradation Understanding what happens to semaglutide at the molecular level as it degrades helps explain why storage conditions matter so much and why expiration dates exist in the first place